OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) major shareholder Jennifer Pritzker sold 10,131 shares of OrthoPediatrics stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.10, for a total transaction of $234,026.10. Following the completion of the transaction, the insider directly owned 6,526,633 shares of the company's stock, valued at approximately $150,765,222.30. This trade represents a 0.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
OrthoPediatrics Stock Performance
Shares of OrthoPediatrics stock traded down $0.31 during trading on Tuesday, hitting $23.00. 139,797 shares of the stock were exchanged, compared to its average volume of 173,766. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The company has a fifty day moving average price of $21.52 and a 200-day moving average price of $18.72. The stock has a market capitalization of $600.53 million, a price-to-earnings ratio of -13.69 and a beta of 0.98. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. As a group, equities analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.
Analyst Ratings Changes
KIDS has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an "overweight" rating and issued a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Needham & Company LLC increased their price target on OrthoPediatrics from $30.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, August 5th. BTIG Research upped their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Finally, TD Cowen reissued a "buy" rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.44.
View Our Latest Stock Report on KIDS
Hedge Funds Weigh In On OrthoPediatrics
Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company's stock worth $26,000 after purchasing an additional 1,139 shares during the period. Legal & General Group Plc bought a new stake in OrthoPediatrics in the 2nd quarter valued at $34,000. Northwestern Mutual Wealth Management Co. boosted its stake in OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company's stock valued at $46,000 after purchasing an additional 2,561 shares during the period. Caption Management LLC acquired a new position in OrthoPediatrics in the 3rd quarter valued at $54,000. Finally, BNP Paribas Financial Markets grew its holdings in OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company's stock valued at $61,000 after buying an additional 1,235 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company's stock.
About OrthoPediatrics
(
Get Free Report)
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.